FDA accepts Pfizer's marketing application for expanded use of Xtandi

|By:, SA News Editor

Pfizer (NYSE:PFE) and collaboration partner Astellas Pharma (OTCPK:ALPMF) announce that the FDA has accepted under Priority Review the former's marketing application seeking approval for XTANDI (enzalutamide) for the treatment of men with non-metastatic castration-resistant prostate cancer (CRPC).

The FDA approved XTANDI in August 2012 for metastatic CRPC.

The agency's action date is in July.